The overall objective of EMVDA is to support the development of vaccines that protect against Plasmodium falciparum malaria in endemic areas. This strain of malaria causes the most morbidity and mortality. To achieve this objective a productive scientific and technological structure, supported by effective management, has been established to move malaria vaccine candidates from preclinical to early phase clinical development. Stringent go/no-go criteria have been established to assess and compare competing antigens and delivery systems. Using this strategy ensures resources are allocated in the most efficient way to the most credible vaccine candidates, the main focus being on moving vaccine candidates into current Good Manufacturing Practice (cGMP) production and Phase I clinical trials.

To select and promote development of the most promising vaccine candidates EMVDA is uniting the capabilities of Small and Medium Enterprises, European malaria vaccine research centres, EVI, and African Partner Groups (already linked through the African Malaria Network Trust (AMANET) as a consortium.

The EMVDA project is organised in six work package groups: 1) candidate antigens, 2) platforms and adjuvants, 3) vaccine development cross-cutting issues including assays for vaccine evaluation, 4) demonstration activities including GMP production and Phase I clinical trials, 5) training, integration and partnership activities, and 6) management activities comprising both consortium management and product development management.

The EMVDA consortium is actively cooperating with other global stakeholders active in the field of malaria vaccine development, and in particular the World Health Organization (WHO). It is participating in, and contributing to, agreed global coordination and harmonisation efforts, as described in the Malaria Vaccine Technology Roadmap.